NewcelX publishes patent application in China for neurology and metabolic diseases treatment.

NewcelX has published a major international patent application in China for a new class of quinazoline, benzothiazine, and benzoxazine derivatives (DOXA) for treating neurological diseases. This marks an expansion of the company's proprietary small-molecule portfolio, supporting its strategy in advancing therapeutic innovation across sleep-wake disorders, neurodegeneration, and metabolic disease.